Tajikistan has received another consignment of Pfizer-BioNTech COVID-19 vaccine through the COVID-19 Vaccines Global Access (COVAX) facility.
An additional 152,100 doses of the Pfizer-BioNTech COVID-19 vaccine was delivered to Tajikistan by the United States through the United States Agency for International Development (USAID) on January 31, according to the Ministry of Health and Social Protection of the Population (MoHSPP).
Before that, the United States 153,000 doses of the Pfizer vaccine to Tajikistan through the USAID on December 31, 2021.
On December 17, 2021, the United States delivered 141,570 doses of the Pfizer vaccine to Tajikistan through the USAID.
The Pfizer–BioNTech COVID-19 vaccine is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech and for its development collaborated with American company Pfizer, for support with clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19. Vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the United States and up to four months in Canada.
The vaccine is the first COVID‑19 vaccine to be authorized by a stringent regulatory authority for emergency use and the first cleared for regular use. In December 2020, the United Kingdom was the first country to authorize its use on an emergency basis. It is authorized for use at some level in the majority of countries. On August 23, 2021, the Pfizer–BioNTech vaccine became the first COVID-19 vaccine to be approved in the United States by the Food and Drug Administration (FDA) for those aged sixteen years and older.
